everolimus
everolimus is listed in the FDA National Drug Code directory with 63 NDC codes, marketed under brand names including Zortress, EVEROLIMUS, everolimus. Available dosage forms: tablet, tablet, for suspension, powder.
Drug details
- Generic Name
- everolimus
- Brand Names
- Zortress, EVEROLIMUS, everolimus, Everolimus, Afinitor Disperz, Afinitor
- Application Number
- NDA021560
- Sponsor
- Novartis Pharmaceuticals Corporation
- NDC Codes
- 63
- Dosage Forms
- TABLET, TABLET, FOR SUSPENSION, POWDER
- Routes
- ORAL
- Active Ingredients
- EVEROLIMUS
Indications and Usage
1 INDICATIONS AND USAGE Everolimus is a kinase inhibitor indicated for the treatment of: • Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) • Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) 1.3 Renal Cell Carcinoma (RCC) Everolimus is indicated for the treatment of adult patients with advanced RCC after failure of treatment with sunitinib or sorafenib. 1.4 Tuberous Sclerosis Complex (TSC)-Associated Renal Angiomyolipoma Everolimus is indicated for the treatment of adult patients with renal angiomyolipoma and TSC, not requiring immediate surgery.